Wound Management Sells Non-Core Subsidiary; Intends to Focus on CellerateRX and Medical Device Business
Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK), an emerging innovator in advanced wound care solutions, has sold its wholly-owned subsidiary, Secure eHealth, LLC (“Secure eHealth”), to two entities that previously financed the acquisition of Secure eHealth by WNDM in January 2010. In...
recent news
Written on Jan 4, 2012
Written on Dec 30, 2011
Written on Dec 29, 2011
Written on Dec 29, 2011
AccuGenomics Seeks to Standardize Gene Expression ...
Founded in 2010, AccuGenomics is a North Carolina-based, privately held genetics testing company focused on providing standardized gene expression tests to accurately diagnose, monitor and inform cancer treatments.
The company has two tests in development to diagnose,...
March 8 – 9, 2012 Korea Investor Conference
Written on Dec 30, 2011Shilla Hotel
Seoul, Korea
The 6th annual Citi Korea Investor Conference has evolved into one of the premier corporate access events in Korea. With over 70 corporates in attendance, investors from around the world can gather in one place for an indepth, first hand look...
Grant Thornton to Sponsor a Workshop on Funding St...
Grant Thornton, an international tax and consulting firm, will sponsor and host a workshop at OneMedForum SF 2012 to discuss funding strategies for life sciences companies. Over the past several years, the primary sources for life science funding have remained largely...
February 27-28 2012 Star Ratings Symposium
Written on Dec 30, 2011Star Ratings Symposium
February 27-28 2012
Crowne Plaza Anaheim Resort, Anaheim, CA
How would your rank your strategy for optimizing CMS’s 5-Star Quality Rating System? Were you a top-rated plan in 2011?
If not, the Star Ratings Symposium is a must-attend...
LoneStar Heart is Focused on Preserving & Res...
LoneStar Heart, Inc. is a Texas and California-based biomedical company focused on developing technologies and therapies to preserve and restore heart functions to patients with congestive heart failure (CHF).
Congestive heart failure affects as many as 5 million...
CorInnova is Developing Technologies to Restore He...
CorInnova, Inc. is a privately held biomedical device company based in Houston, Texas. The company develops technologies aimed at recovery for patients with end stage heart failure. Their target market is 70,000 bedridden American heart failure patients with irregular...
popular news
- Non-Invasive Glucose Monitor Cleared in Europe (14)
- InSound Medical's Lyric: A Long Time Coming (11)
- New Study Highlights Promising Gene-Based Predictor of Prostate Cancer Risk (8)
- [Quick Take] Interview with Jeff Rencher, President of Sales & Marketing at Opticon Medical (6)
- Revolution Health Takes on WebMD with User-Centric Focus (5)
- Blue Shield of California Sees the 308-nanometer Light (5)
- srebrenik shalom: we invested a lot of money in ADXS from the very begining an...
- Alan S. Frankel: This conference call was excellent and I hope to follow Adva...
- Copd untreated: What's COPD? COPD = continual Obstructive lung. Do you kn...
- nicolette richards: I am 19 years old and I have trisomy 20 mosaicism and I was ...
- eric: brett, thanks for this interview i just became a sharehold...
- Jonathan Stuart: Pre-IPO funds are also run by MidasLP.com, GSV and several o...
recent from News
Wound Management Sells Non-Core Subsidiary; Intends to Focus on CellerateRX and Medical Device Business
Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK), an emerging innovator in advanced wound care solutions, has sold its wholly-owned subsidiary, Secure eHealth, LLC (“Secure eHealth”), to two entities that previously financed the acquisition of Secure eHealth by WNDM in January 2010. In...
Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK), an emerging innovator in advanced wound care solutions, has sold its wholly-owned subsidiary, Secure eHealth, LLC (“Secure eHealth”), to two entities that previously financed the acquisition of Secure eHealth by WNDM in January 2010. In...
recent from Research
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
recent from Profiles
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
recent from Video
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America.
Its sixth OneMedForum, and second in New York, OneMedPlace will focus on critical success factors for building companies on both sides of the...
